Hematopoietic stem cell transplants (HSCTs) are considered the best treatment option for many hematological malignancies, and transplant numbers have increased five-fold during the last decade. Only a few controlled prospective studies are available, and different opinions prevail. Data from 118 167 HSCT (36% allogeneic, 64% autologous) collected within the EBMT activity survey from 1990 to 2001 were used to assess trends over time, transplant rates and coefficient of variation (CV) of transplant rates among European countries for acute myeloid leukemia (AML; 18.5%), acute lymphocytic leukemia (ALL; 12%), chronic myeloid leukemia (CML; 11.5%), myelodysplastic syndromes (MDS; 3%), lymphoproliferative disorders (LPS; 36.3%) and multiple myeloma (MM; 18.7%). Transplant rates increased in all countries and for all indications from 1990 to 2001 from 1.7-fold (CML) to 24.8-fold (MM). Transplant rates have declined for CML since 1999. Autologous HSCT are the preferred choice for LPS and MM, allogeneic HSCT for ALL and myeloid malignancies. CVs of less than 50% suggest consensus for allogeneic HSCT in AML, ALL, CML, MDS and NHL, for autologous HSCT in LPS and MM. These data give an overview of the current status of HSCT for hematological malignancies in Europe and provide objective information for health-care providers and patient counselling. Leukemia (2003) 17, 941-959.
Introduction
Hematological malignancies currently represent the main indications for hematopoietic stem cell transplantation (HSCT). [1] [2] [3] [4] [5] Clearly, autologous and allogeneic HSCT are established therapy in many situations and are integrated in the therapeutic strategy of most large multicenter cooperative study group trials. There are, however, few prospective randomized controlled trials comparing HSCT with standard conventional chemotherapy, and different opinions exist. [6] [7] [8] [9] [10] [11] [12] [13] Recent publications have pointed in detail to the differences in therapeutic strategies for patients with leukemias in Europe or the US. [14] [15] [16] Similarly, differences in transplant rate for certain hematological malignancies between European countries have been previously described. 17 In addition, opinions can undergo rapid change, as was illustrated by the increase and decrease in HSCT for indications, such as breast cancer in the mid1990s, 18, 19 and chronic myeloid leukemia (CML) in the last 2 years. 20 Assessment of best strategy for individual indications is further complicated by the factor of time. Generation of data based on evidence takes time. Even large cooperative groups take several years to recruit sufficient numbers of patients and additional years of follow-up are required for meaningful analyses. This situation is of specific importance when comparisons involve strategies with initial high risk, for example, early transplantrelated mortality and late benefits, for example, graft-versustumor effects. Evaluation at early time points gives different outcomes than evaluation at 10 years from treatment. [21] [22] [23] In addition, at the time of late analysis technologies might have changed, new methods been developed or more specific drug treatment been introduced. Change from bone marrow to peripheral blood, reduced intensity conditioning transplants or imatinib mesylate as drug for CML are such examples. 5, 10, [24] [25] [26] Patients and treating physicians in contrast depend on an optimum of information for treatment decisions today. Large comprehensive observational databases provide an instrument to reflect current strategies. Taking the annual EBMT activity survey as a basis, 5 we therefore present a detailed analysis of the current HSCT strategy for hematological malignancies in Europe, including changes over time in transplant numbers and differences in transplant rates between European countries over the last 12 years. They describe current thinking of specialist teams in Europe.
Patients and methods

Data collection, selection and validation
Data derived for these analyses come from the EBMT activity surveys introduced in 1990. 27 All EBMT members and affiliated nonmembers receive an annual survey sheet on which they can report numbers of patients by indication, stem cell source and donor type for the past year. This report includes data from 1990 up to and including 2001. This analysis includes hematological malignancies defined and classified as acute myeloid leukemia (AML), acute lymphocytic leukemia (ALL), CML, myelodysplastic syndromes (MDS), lymphoproliferative syndromes (LPS), with the subgroups non-Hodgkin's lymphoma (NHL), Hodgkin's lymphoma (HD) and chronic lymphocytic leukemia (CLL) and multiple myeloma (MM) ( Table 1) . Additional information on the stage of the disease was available for AML (first complete remission (CR) vs nonfirst CR), ALL (first CR vs nonfirst CR) and CML (first chronic phase vs nonfirst chronic phase). This information on disease stage at the time of transplant is not available for the other disease categories.
The EBMT survey forms an integral part of a prospective quality assurance program conducted by the EBMT (http:// www.ebmt.org). Validation of data includes returning a computer print out of entered data to the reporting teams, crosschecking with national transplant registries and onsite visits.
Participating countries and teams
The report is based on 624 teams from 37 European countries. Transplant rates: Transplant rates were defined as the number of HSCT per ten million inhabitants. They were computed for each disease indication, donor type and country. For each disease indication, transplant rates were assessed for all HSCT and separately for autologous and allogeneic HSCT. Population data were obtained from the US Census Office (http://www.census.gov).
Coefficient of variation:
Coefficients of variation (CV) of transplant rates were calculated, as previously defined 28 , for each disease indication by donor type and, if applicable, disease stage (CV (%) ¼ (standard deviation (s.d.)/mean Â 100). To ascertain homogeneity, only those countries were included in the CV analysis which had more than 300 HSCT in 2001 ( Table 2 ). The increase in numbers and absolute numbers of HSCT per year for main disease categories is illustrated in Figure 1 . There is an increase in all indications except for CML in the last 2 years. The slope of the curve reflecting the rate of increase since 1990 differs for individual disease categories and is highest for MM. Transplants increased 1.7-fold for CML, 1.9-fold for AML, 6.1-fold for MDS, 6.9-fold for LPS and 2.5-fold for MM (overall 4.8-fold).
Both allogeneic and autologous HSCT were used for all indications, but not to the same extent. The proportion of allogeneic compared to autologous transplants differed in individual disease categories and changed over time for some but not all disease categories, as illustrated in Figure 2 . The highest proportion of allogeneic transplants was found in CML (95%) and MDS (93%), the lowest for MM (6%) and LPS (12%).
This difference in evolution of transplant numbers over time for allogeneic and autologous HSCT is further illustrated by separation into disease subcategories ( Figure 3 ). For AML, similar numbers and trends were observed in first CR for allogeneic and autologous HSCT and similar numbers of allogeneic HSCT are performed in first CR or at later stages ( Figure 3a ). Autologous HSCT beyond first CR were done in low numbers throughout the observation period. In contrast, in ALL autologous HSCT remained low and more allogeneic HSCT 1990  882  778  615  90  928  176  3469  1991  1022  815  635  95  1166  306  4039  1992  1158  910  735  142  1535  373  4853  1993  1397  976  854  171  2091  596  6085  1994  1618  1020  993  216  2752  1042  7641  1995  1696  1246  1099  289  3347  1402  9079  1996  1889  1284  1386  306  3732  1869  10 466  1997  2005  1299  1453  354  4527  2388  12 026  1998  2333  1440  1607  374  5096  2657  13 507  1999  2445  1431  1686  436  5326  3184  14 HSCT for hematological malignancies A Gratwohl et al HSCT for hematological malignancies A Gratwohl et al were performed beyond first CR (Figure 3b) . CML was the leading indication up to 1999 with continuously increasing numbers of allogeneic and autologous HSCT. In 2001, autologous HSCT nearly ceased and allogeneic HSCT had dropped by 30% (Figure 3c ). In CLL, interest in HSCT had increased since 1996, initially with autologous HSCT, more recently with allogeneic HSCT (Figure 3c ). In MDS, there was an increase but limited to allogeneic HSCT with only steady, small numbers of autologous HSCT (Figure 3d ). The reverse situation was observed in MM. There was a massive increase in HSCT for hematological malignancies A Gratwohl et al autologous HSCT, but only a small increase in allogeneic HSCT (Figure 3f ). The situation was similar for lymphomas with a primary increase in autologous HSCT and only a small increase in allogeneic HSCT for NHL over the last 3 years (Figure 3g ). (Figure 4) . Transplant rates for all transplants, including both allogeneic and autologous HSCT, varied from 0 (several countries) to more than 400 per ten million inhabitants (several countries). The same basic difference in transplant rates between Eastern and Western European countries was observed if individual disease indications were represented by transplant rates ( Figure 5 ). In addition, there was a marked over or under representation for certain disease indications (Figure 5a-c) . Few transplants were performed in 2001 for CML in France (Figure 5c ). Myeloma transplants were higher in France, Italy and the Nordic states ( Figure 5e ) and MDS transplants were higher in the Benelux states, Germany, Switzerland, Spain and Sweden (Figure 5d ).
Transplant rates in European countries
Coefficient of variation
The visual differences in transplant rates for the individual disease indications (Figure 5s ) was quantified by the CV. In order to adjust for the economic impact, this analysis was restricted to the 12 selected countries with more than 300 HSCT in 2001 ( Table 4 . Variation is lowest for autologous HSCT for NHL (19.2%) and highest for autologous HSCT for CML beyond first CP (132.1%). It permits classification of disease into categories with high consensus (CV o50%), intermediate consensus and no consensus (CV 480%) among the specialist teams concerning indications for HSCT. By using this approach, acute leukemias, CML, MDS and NHL were considered as accepted indications for allogeneic, MM, NHL and HD for autologous HSCT. In contrast, HD for allogeneic and ALL, CML, MDS and CLL for autologous, were not regarded as established indications for HSCT.
Discussion
These data give a clear view of the current status of HSCT for hematological malignancies in Europe today, point to the changes in transplant rates over the last decade and illustrate similarities and discrepancies between the European countries. They illustrate the continuing increase for some disease categories, stable situations for others as well as increase and decrease for CML. In general, these trends reflect the prevailing considerations of transplant physicians and specialists in the field about the advantage or disadvantage for HSCT: an increase points to consensus on advantage of HSCT, stable low numbers reflect the experimental status of the procedure and decreasing numbers the advent of alternative therapies or a disadvantage of HSCT. In this context, it is comforting to see that CVs of HSCT for hematological malignancies A Gratwohl et al transplant rates are low in situations where prospective studies exist and where expert opinions agree. 6, 7, 13, 29, 30, [41] [42] [43] CVs provide an objective instrument for consensus assessment. 28 Data of this survey highlight to an additional conflict of interest, as illustrated by the difference in transplant rates for indications, such as MM or MDS. There are no data that disease prevalence is different in European countries. Hence transplant rates should be no different, if indications were agreed upon. These differences might reflect the impact of presence or absence of ongoing active study protocols by the respective national and regional study groups. As such, a lower transplant rate might reflect absence, higher transplant rate, presence of a specific national study group protocol. Little or no information exists with regard to these aspects. A need for studies on decision-making at team level has been illustrated by the rapid decline in HSCT rates for CML, which began in 1999, 2 years ahead of any published data on the use of imatinib in CML treatment and far ahead of any studies on long-term outcome. Anticipation as the driving force has been discussed in this context. 20 Data on comprehensive surveys, such as the EBMT activity survey, might at least give an objective analysis of the current status, when more than 95% of activity in the field is captured. These surveys cannot substitute for prospective control studies, but will become even more important when 10 years or more of follow-up are required for long-term analyses. As an example, all comparisons of allogeneic and autologous HSCT are hampered by two well-known facts. 6, 8, 9, 19, 31, 32 Allogeneic HSCT is always associated with higher initial TRM, but a lower late relapse rate. 3, 33, 44 The balance of these events is never equal. Early events need limited observation time, late balance of graft-versus-host and graft-versus-tumor effects depends on the evolution of acute and chronic graft-versus-host disease, its prevention and treatment, application of donor lymphocyte infusions and/or concomitant chemotherapy treatment. 21, 22, 34 In situations with long follow-up, we risk comparing technologies which are no longer in use at the time of analysis. This is clearly the case for comparisons of chemotherapy and autologous HSCT in AML. 9 Bone marrow was a traditional source in 1990, 27 but it is hardly used today and has been replaced by peripheral blood. 5 Comparative studies with peripheral blood, in contrast, are still ongoing or short of follow-up. 8, 9 The same holds true for the new technologies in allogeneic HSCT, such as reduced intensity conditioning. [34] [35] [36] [37] [38] [39] [40] Increased use has been seen over the last 3 years. 24 Effects of graft-versus-host and graftversus-tumor effects are too early to be evaluated correctly. Only extrapolations are valid. However, decisions at individual patient and team level must be made.
As such, this present analysis does not give any data on outcome. This information is gathered elsewhere and published separately. This survey just concentrates on rapid description of the current status quo. It reflects the situation of HSCT for hematological malignancies in Europe, gives information on consensus or dissents among specialists in the field and provides an objective basis for patient counselling and health-care planning. 
